I think the current trial (N=10) is too small to produce reliable efficacy results (negative or positive). Normally Phase 2a is a safety trial, with any efficacy data a bonus. The earlier trial was large enough to produce statistically significant data for DKD sufferers, but I believe had no FSGS sufferers at all, hence the need for the current FSGS Phase 2a trial.
But yes it would be disappointing if there was no indication at all of positive results for FSGS.
- Forums
- ASX - By Stock
- DXB
- Ann: Quarterly Appendix 4C and Activities Report
Ann: Quarterly Appendix 4C and Activities Report, page-207
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
38.0¢ |
Change
-0.025(6.17%) |
Mkt cap ! $203.7M |
Open | High | Low | Value | Volume |
41.5¢ | 41.5¢ | 37.0¢ | $2.268M | 5.905M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 192224 | 37.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 51800 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 192224 | 0.375 |
22 | 456769 | 0.370 |
13 | 208281 | 0.365 |
14 | 238454 | 0.360 |
6 | 353040 | 0.355 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 51800 | 2 |
0.385 | 150455 | 8 |
0.390 | 130216 | 7 |
0.395 | 25400 | 3 |
0.400 | 90064 | 6 |
Last trade - 13.03pm 10/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |